Hively Brad
SEC Form 4 insider trading activity
Hively Brad has filed 4 SEC Form 4 filings (5 transaction rows) across 2 companies, including STLN, TOI, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Aug 24, 2026.
On the most recent filing, Hively Brad is listed as Director at Starling Oncology, Inc. Inside the rolling window, Hively Brad reported no open-market purchases and 2 open-market sales totaling $2.0M in STLN and TOI. The largest disclosed transaction in the window is a sale of 298,853 STLN shares on Aug 21, 2026, worth $1.9M.
Companies traded
Other insiders at STLN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.0M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hively Brad made?
Hively Brad has filed 4 SEC Form 4 filings (5 transaction rows) across 2 companies, including STLN, TOI since 2025.
Which companies does Hively Brad trade?
Hively Brad has filed SEC Form 4 disclosures for 2 companies, including STLN, TOI.
When was Hively Brad's most recent SEC Form 4 filing?
Hively Brad's most recent SEC Form 4 filing on Tracefour is dated Aug 24, 2026.
What is Hively Brad's total buy and sell value in the current window?
Inside the rolling retention window, Hively Brad bought $0 and sold $2.0M based on SEC Form 4 filings.
What was Hively Brad's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 298,853 STLN shares on 2026-08-21, worth $1.9M, per SEC Form 4 filings.